Aperio Group’s Trinity Biotech TRIB Stock Holding History

Aperio Group’s Portfolio TRIB Stock Details TRIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-650	Closed	-$5K	–	2728
2019 Q2	$5K	Buy	+650	New	+$7.73K	﹤0.01%	2862

Other funds holding TRIB

SCM

Stonehill Capital Management New York $197M AUM 96.45% 1-Year Est. Return

PIM

Paradice Investment Management Denver, Colorado $532M AUM 29.6% 1-Year Est. Return

HAIM

Hunter Associates Investment Management Pittsburgh, Pennsylvania $756M AUM 19.99% 1-Year Est. Return

FWSM

First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fondren Management Houston, Texas $16.9M AUM 5.82% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ARM

Adirondack Research & Management Guilderland, New York $82.2M AUM 63.78% 1-Year Est. Return

Aperio Group's TRIB Position: Q3 2019 in Review

Aperio Group sold out of Trinity Biotech (TRIB) in Q3 2019, closing a stake of 650 shares — an estimated $5K sold.

Aperio Group first reported a position in TRIB in Q2 2019 and held it in 1 quarter. The position peaked at $5K in Q2 2019. 29 funds tracked by Wall St. Rank hold TRIB as of Q3 2019.

Aperio Group reported no remaining Trinity Biotech position as of Q3 2019 after selling out during the quarter.
Aperio Group sold 650 Trinity Biotech shares in Q3 2019, an estimated $5K.
Aperio Group first reported a position in Trinity Biotech in Q2 2019 and held it in 1 quarter.
Aperio Group's Trinity Biotech position peaked at $5K in Q2 2019.
29 funds tracked by Wall St. Rank held Trinity Biotech as of Q3 2019.

Based on Aperio Group's 13F filing for Q3 2019, filed 6 Nov 2019.